Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Price-Fixing Lawsuit Grows As More Companies, Two Executives Named Defendants

Executive Summary

US state attorneys general name executives from Mylan and Emcure as defendants, and list may further expand as investigation continues into additional companies and drugs.

You may also be interested in...



Two India Firms In Fresh FDA Trouble: Emcure Hit By Warning Letter, Dr Reddy’s Gets 483

The US regulator has slammed India’s Emcure Pharmaceuticals in a warning letter, accusing the company of slipshod investigation of tests showing microbial contamination and poor supervision, and has also sent a Form 483 containing eight observations to Dr Reddy’s.

Heritage Is First To Settle DOJ Generic Drug Price Fixing Probe

Heritage agrees to pay $7.1m to resolve civil allegations and a $225,000 criminal penalty. DOJ defers prosecution of one felony charge.

Heritage Is First To Settle DOJ Generic Drug Price Fixing Probe; Will Others Follow?

Heritage agrees to pay $7.1m to resolve civil allegations and a $225,000 criminal penalty. DOJ defers prosecution of one felony charge.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel